Related Experiment Video
Updated: Aug 18, 2026
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
Insights
Neuroblastoma survival in children is not linked to current treatments but depends on disease stage and patient age. Management strategies are being developed based on disease staging for better outcomes.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Clinical Management
Background:
- Abdominal neuroblastoma is a challenging pediatric cancer.
- Current therapeutic efforts show limited impact on overall survival.
- A staging-based management approach is under development.
Purpose of the Study:
- To develop a management strategy for neuroblastoma based on disease stage.
- To analyze survival rates in relation to disease stage and patient age.
- To evaluate the efficacy of different treatment modalities.
Main Methods:
- Retrospective analysis of neuroblastoma cases.
- Correlation of survival rates with disease stage (I-IV).
- Assessment of treatment modalities including surgery, irradiation, and chemotherapy.
Main Results:
- Seventy-three percent of patients present with metastases at diagnosis.
- Survival is highest in infants under 1 year of age.
- Survival rates decrease significantly with advanced disease stages (90% Stage I to 2.4% Stage IV).
- Irradiation therapy showed no survival benefit in Stages I, II, and IV.
- Chemotherapy did not alter survival rates across any stage.
- Surgical tumor removal remains the primary treatment.
- Irradiation demonstrated significant benefit in Stage III disease.
Conclusions:
- Neuroblastoma management requires a stage-specific approach.
- Early diagnosis and surgical intervention are crucial.
- Further research is needed to improve therapeutic efficacy for advanced stages.
Abstract:
Although survival of children with abdominal neuroblastoma seems at this time to be unrelated to the therapeutic effort, a method of management according to the stage of disease has been developed. Seventy-three percent of patients have metastases at the time of diagnosis. Survival is best in children under 1 year of age. Survival by stage of disease drops progressively from 90% in Stage I disease to 2.4% in Stage IV disease. Irradiation therapy seems unrelated to survival in Stage I, II, and IV disease, while chemotherapy has not been shown to alter survival rates in any stage. Surgical removal of the tumor is still the primary therapy; irradiation is of significant benefit in patients with Stage III disease.
